Evidence map›Paper›PMID 28754021›Full record

ReviewInternational journal of molecular sciences2017

DNA Damage Tolerance by Eukaryotic DNA Polymerase and Primase PrimPol.

Elizaveta O Boldinova, Paulina H Wanrooij, Evgeniy S Shilkin, Sjoerd Wanrooij, Alena V Makarova

Abstract readReview
In one paragraph

Review in International journal of molecular sciences, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. PARP Inhibition and Beyond in BRCA-Associated Breast Cancer in Women: A State-Of-The-Art Summary of Preclinical Research on Risk Reduction and Clinical Benefits.Medical principles and practice : international journal of the Kuwait University, Health Science Centre · 2022
    Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Chemically-Induced DNA Damage, Mutagenesis, and Cancer.International journal of molecular sciences · 2018
    Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Elizaveta O BoldinovaInstitute of Molecular Genetics of Russian Academy of Sciences, Kurchatov sq. 2, 123182 Moscow, Russia. lizaboldinova@yandex.ru.
Paulina H WanrooijDepartment of Medical Biochemistry and Biophysics, Umeå University, 901 87 Umeå, Sweden. paulina.wanrooij@umu.se.
Evgeniy S ShilkinInstitute of Molecular Genetics of Russian Academy of Sciences, Kurchatov sq. 2, 123182 Moscow, Russia. shilkinevgeniy.chem@gmail.com.
Sjoerd WanrooijDepartment of Medical Biochemistry and Biophysics, Umeå University, 901 87 Umeå, Sweden. sjoerd.wanrooij@umu.se.
Alena V MakarovaInstitute of Molecular Genetics of Russian Academy of Sciences, Kurchatov sq. 2, 123182 Moscow, Russia. amakarova-img@yandex.ru.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PrimPol is a human deoxyribonucleic acid (DNA) polymerase that also possesses primase activity and is involved in DNA damage tolerance, the prevention of genome instability and mitochondrial DNA maintenance. In this review, we focus on recent advances in biochemical and crystallographic studies of PrimPol, as well as in identification of new protein-protein interaction partners. Furthermore, we discuss the possible functions of PrimPol in both the nucleus and the mitochondria.

Indexed as

DNA DamageCell NucleusCrystallographyDNA-Directed DNA PolymeraseDNA, MitochondrialDNA PrimaseDNA ReplicationGenomic InstabilityHumansMitochondriaMultifunctional EnzymesDNA-Directed DNA PolymeraseDNA, MitochondrialDNA PrimaseMultifunctional EnzymesPrimPol protein, humanDNA damagemitochondriaPrimPolreplication

Identifiers

PMID28754021
PMCPMC5536071

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.